Hormone replacement therapy causes a decrease in hepatocyte growth factor in hypertensive women

Journal of Hypertension

Volumn 21, Issue 6, 2003, Pages 1151-1156

  Tamama, Kenichi ^a   Sumino, Hiroyuki ^a   Ichikawa, Shuichi ^b   Kanda, Tsugiyasu ^c   Kotajima, Nobuo ^a   Fukumura, Yukihito ^a   Kurabayashi, Masahiko ^a   Murakami, Masami ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Cardiovascular Hospital of Central Japan   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood pressure; Estrogen; Growth substances; Hypertension; Women

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; SCATTER FACTOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 0037865205     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200306000-00015     Document Type: Article

References (27)

1. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
2. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991; 18(Suppl): III115-III121.
3. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors: additive stimulatory effect of HGF with basic fibroblast growth factor, but not vascular endothelial growth factor. J Hypertens 1996; 14:1067-1072.
4. Nakano N, Morishita R, Moriguchi A, Nakamura Y, Hayashi SI, Aoki M, et al. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 1998; 32:444-451.
5. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996; 28:409-413.
6. Nakamura S, Moriguchi A, Morishita R, Aoki M, Yo Y, Hayashi S, et al. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem Biophys Res Commun 1998; 242:238-243.
7. Nishimura M, Ushiyama M, Nanbu A, Ohtsuka K, Takahashi H, Yoshimura M. Serum hepatocyte growth factor as a possible indicator of arteriosclerosis. J Hypertens 1997; 15:1137-1142.
8. Nishimura M, Nakano K, Ushiyama M, Nanbu A, Ohtsuka K, Takahashi H, et al. Increased serum concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. J Clin Endocrinol Metab 1998; 83:195-198.
9. Higashi Y, Sanada M, Sasaki S, Nakagawa K, Goto C, Matsuura H, et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001; 37:651-657.
10. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121:936-941.
11. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90:786-791.
12. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, Calif, revisited. JAMA 1989; 261:2095-2100.
13. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 1999; 354:650.
14. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels. BMJ 1973; 1:449-451.
15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
16. Sumino H, Nakamura T, Ichikawa S, Kanda T, Sakamaki T, Sato K, et al. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia. Atherosclerosis 2000; 148:189-195.
17. Nakano N, Moriguchi A, Morishita R, Kida I, Tomita N, Matsumoto K, et al. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension 1997; 30:1448-1454.
18. Liu Y, Lin L, Zarnegar R. Modulation of hepatocyte growth factor gene expression by estrogen in mouse ovary. Mol Cell Endocrinol 1994; 104:173-181.
19. Jiang JG, Bell A, Liu Y, Zarnegar R. Transcriptional regulation of the hepatocyte growth factor gene by the nuclear receptors chicken ovalbumin upstream promoter transcription factor and estrogen receptor. J Biol Chem 1997; 272:3928-3934.
20. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328:1069-1075.
21. Kornhauser C, Malacara JM, Garay ME, Perez-Luque EL. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens 1997; 11:405-411.
22. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women; the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208.
23. Sumino H, Ichikawa S, Kanda T, Sakamaki T, Nakamura T, Sato K, et al. Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. Am J Hypertens 1999; 12:1044-1047.
24. Nogawa N, Sumino H, Ichikawa S, Kumakura H, Takayama Y, Nakamura T, et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001; 8:210-215.
25. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 2001; 14:206-211.
26. Miya Y, Sumino H, Ichikawa S, Nakamura T, Kanda T, Kumakura H, et al. Effects of hormone replacement therapy on left ventricular hypertrophy and growth- promoting factors in hypertensive postmenopausal women. Hypertens Res 2002; 25:153-159.
27. Sumino H, Ichikawa S, Ohyama Y, Nakamura T, Kanda T, Sakamoto H, et al. Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res 2003; 26:53-58.